{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Drugs.com Monthly Update Podcast","title":"Drugs.com - Monthly Update April 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/800cee99\"></iframe>","width":"100%","height":180,"duration":305,"description":"In this April 2026 Monthly Update edition, we highlight several FDA approvals that introduce first-of-their-kind therapies and improve access to existing treatments.Foundayo (orforglipron): A first-of-its-kind small-molecule oral GLP-1 receptor agonist for chronic weight management without strict food or water requirements.Otarmeni (lunsotogene parvec-cwha): An innovative gene therapy for pediatric and adult patients with OTOF-related genetic hearing loss.Idvynso (doravirine and islatravir): A new once-daily, two-drug single-tablet regimen for adults with HIV-1 who are virologically suppressed.Langlara (insulin glargine-aldy): A interchangeable biosimilar to Lantus for the treatment of type 1 and type 2 diabetes.Chapters:Follow Drugs.com:X, Facebook, YouTubeSign up to our newslettersDownload the app","thumbnail_url":"https://img.transistorcdn.com/DIoKA3oI7NY0UzZ45F0V0NkzM-ycfQHBYCciiz9juOc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mMDAz/YzA5MzEzMjc1MDA5/YjRmMjFmMDA1MjYy/YmZmZC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}